CurrentHealth NetPolicy N/A

Pegcetacoplan (Empaveli, Syfovre) clinical policy

Defines coverage, dosing, coding, and clinical considerations for pegcetacoplan products (subcutaneous and intravitreal) for indications including PNH, C3G/IC-MPGN, and geographic atrophy; intended for providers and utilization reviewers within the Health Net plan.

Policy Summary

PayerHealth Net

PolicyPegcetacoplan (Empaveli, Syfovre) clinical policy

Policy CodePolicy N/A

Change TypeRevised — material updates (2024–2025)

Effective DateMay 14, 2021

Next Review DateN/A

Key ActionSubmit prior authorization with indication, imaging confirmation for GA, and documentation of prior/concomitant therapies.

SourceLink

POLICY UPDATE CHANGES

For PNH, added Epysqli and PiaSky to the list of therapies that Empaveli should not be prescribed concurrently with; added improvement of extravascular hemolysis as an example of positive response; revised continued approval duration from 6 to 12 months.

Clarified diagnostic characteristics for GA must be confirmed on fundus autofluorescence imaging and updated Syfovre contraindications to include hypersensitivity.

Added HCPCS code J2781 for pegcetacoplan and removed inactive HCPCS code C9151.

J2781HCPCS J2781

1,080 mgEmpaveli SC dose

15 mg/0.1 mLSyfovre concentration

12 monthsContinued approval (PNH)

Indications and Coverage Rules

Indication-specific coverage criteria

Coverage and treatment conditions referenced for specific indications (PNH, C3G/IC‑MPGN, GA):

PNH initial therapy: Adults receive Empaveli 1,080 mg subcutaneously twice weekly; when switching from Soliris, Bkemv, or Epysqli initiate Empaveli while continuing the prior agent at its current dose for 4 weeks, then discontinue the prior agent and continue Empaveli monotherapy; when switching from Ultomiris initiate Empaveli no more than 4 weeks after the last Ultomiris dose.LDH >= 2x ULN adjustment applies

Empaveli contraindications include concurrent use with specified complement inhibitors (see policy appendices); continued approval duration for PNH is 12 months and improvement of extravascular hemolysis may be considered a positive response.

C3G / IC‑MPGN: Empaveli dosing is weight‑based: adults and pediatric members >= 50 kg: 1,080 mg SC twice weekly; 35 to <50 kg: 810 mg SC twice weekly; <=35 kg: 648 mg SC twice weekly.weight-based dosing

KDIGO guidance recommends RAAS inhibitor supportive therapy for glomerulonephritis with proteinuria.

Policy Summary

PayerHealth Net

PolicyPegcetacoplan (Empaveli, Syfovre) clinical policy

Policy CodePolicy N/A

Change TypeRevised — material updates (2024–2025)

Effective DateMay 14, 2021

Next Review DateN/A

Key ActionSubmit prior authorization with indication, imaging confirmation for GA, and documentation of prior/concomitant therapies.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Prior Authorization, Documentation, and Switching Guidance

Prior Authorization

Prior Authorization Required

Prior authorization required. Include indication-specific documentation and imaging confirmation for geographic atrophy (GA) when applicable. Requests for Empaveli (pegcetacoplan) or intravitreal pegcetacoplan (Syfovre/APL-2) must include clinical indication, prior and concurrent complement inhibitor therapies, and supporting diagnostic imaging or laboratory data as described below.

Required: clinical indication (e.g., PNH, C3G/IC-MPGN, GA)
Required: full medication history including dates/doses for complement inhibitors (e.g., Soliris/eculizumab, Ultomiris/ravulizumab, Bkemv, Fabhalta, Voydeya, Epysqli, PiaSky)
For PNH switching: document cross-titration plan per dosing guidance (see switching/cross-titration callout)

Note

Switching / Cross-titration Guidance

When transitioning patients between complement inhibitors, initiate Empaveli while continuing the incumbent complement inhibitor at its current dose for a 4-week cross-titration period when switching from eculizumab (Soliris) or similar agents; discontinue the prior complement inhibitor after 4 weeks and continue Empaveli as monotherapy. When switching from ravulizumab (Ultomiris), initiate Empaveli no more than 4 weeks after the last Ultomiris dose. Document the date of last dose of the prior agent, planned Empaveli start date, and the planned date to stop the prior agent. Monitor hemolysis markers (LDH) and adjust Empaveli dosing per label if LDH >=2x ULN.

Cross-titration allowed with eculizumab-class agents for an initial 4-week overlap only
For switches from Ultomiris (ravulizumab), Empaveli initiation must occur within 4 weeks of last Ultomiris dose
Documentation required: last dose date of prior agent, Empaveli initiation date, planned discontinuation date of prior agent, baseline and follow-up LDH values

Documentation Required

Required Diagnostic Documentation for GA (Fundus Autofluorescence)

For GA (geographic atrophy) due to AMD, confirm diagnostic imaging characteristics on fundus autofluorescence (FAF) per pivotal trial alignment and health plan request. Include high-quality FAF images and accompanying reports; when available, include color fundus photography and OCT to support lesion characterization. Describe laterality and measure area of GA if reported. Failure to provide required imaging may result in denial or delayed authorization.

Required imaging: fundus autofluorescence (FAF) confirming GA diagnostic characteristics
Supplemental imaging recommended: OCT and color fundus photography
Include imaging reports, dates, and eye(s) treated; quantify GA area if available

Denial Risk

Concurrent Therapy Contraindications and Denial Risk

Concurrent therapy contraindications: Empaveli should not be prescribed concurrently with other complement inhibitors except for the limited cross-titration periods described. Concurrent use with listed agents is a contraindication and may lead to non-coverage.

Do not authorize concurrent use of Empaveli with Fabhalta, Voydeya, Bkemv, Epysqli, PiaSky, Soliris (except for the 4-week cross-titration exception), Ultomiris (initiate within 4 weeks after last dose rather than concurrent)
Concurrent intravitreal Syfovre with systemic complement inhibitors is disallowed unless explicitly supported by clinical rationale and prior authorization review
Noncompliance with these restrictions may result in denial of the request

Clinical Background

Pegcetacoplan is a complement C3 inhibitor used in both systemic and ocular formulations. For paroxysmal nocturnal hemoglobinuria (PNH) the subcutaneous product (Empaveli) is dosed in adults as 1,080 mg SC twice weekly with specific switching guidance when transitioning from other complement inhibitors (for example, starting Empaveli while continuing Soliris/Bkemv/Episitiri for an initial cross‑titration period). Weight‑based dosing is specified for pediatric or lower‑weight patients in non‑GA indications. An intravitreal formulation (Syfovre) is indicated for geographic atrophy (GA) secondary to AMD with product concentration and dosing per labeling; the policy requires diagnostic confirmation on fundus autofluorescence imaging for GA evaluations. Policy updates also clarify contraindications and coadministration restrictions with other complement inhibitors and note ongoing monitoring considerations such as adjustments for elevated LDH.

J2781	Injection, pegcetacoplan, intravitreal, 1 mg
J7799	Not otherwise classified drugs, administered through DME drugs
C9151	Inactive HCPCS code removed

OpenPayer

Pegcetacoplan (Empaveli, Syfovre) clinical policy

Indications and Coverage Rules

HCPCS and Related Codes

Prior Authorization, Documentation, and Switching Guidance

Key Definitions

Clinical Background